{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-069473","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.244071+00:00","generated_at":"2026-06-14T04:54:26.677933+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem shows 45% ORR in LGSOC at ASCO; plans accelerated filing","bullets":["Updated RAMP 201 Part A: confirmed ORR 45% in recurrent LGSOC; 86% tumor shrinkage.","FDA Breakthrough Therapy for avutometinib + defactinib; accelerated approval filing planned.","Cash $111M as of Q1 2023; up to $150M credit facility; up to $95M milestones from Secura Bio.","Avutometinib shows best-in-class potential; expanding into NSCLC, pancreatic, CRC trials.","Confirmatory trial for LGSOC initiation expected in H2 2023; multiple readouts in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-069473","json":"https://secwatch.observer/filing/0001104659-23-069473.json","markdown":"https://secwatch.observer/filing/0001104659-23-069473.md","text":"https://secwatch.observer/filing/0001104659-23-069473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465923069473/0001104659-23-069473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465923069473/tm2318212d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:54:26.677933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}